Objective
“PANOSTICS” comprises the validation and clinical implementation of a versatile and cost effective diagnostic blood test for the detection of primary aldosteronism (PA) among hypertensive patients. The Aldosterone-to-Angiotensin II-Ratio (AA2-Ratio) is a mass spectrometry based diagnostic biomarker for PA. We are planning to sell this diagnostic blood test to clinical institutions in a fee-for-service business model. Our vision is to build up a European network of qualified fee-for-service laboratories focused on hypertension-associated biomarkers. The market entry for the AA2-Ratio is planned via a subsidiary laboratory in Germany. Full commercialization of the AA2-Ratio shall be achieved by implementation into standard clinical practice for the classification and treatment of resistant hypertension.
Hypertension has been clearly shown to be the most important cause of morbidity and mortality worldwide, representing a severe challenge for future healthcare systems. Up to 11,9 million people in Europe are referred to be resistant hypertensive, meaning that they cannot be cured by standard treatments. PA is a certain form of resistant hypertension that can be easily cured by appropriate second-line drug treatments or surgical procedures, if detected. Recommendations by clinical societies suggest extensive screening efforts to facilitate an early detection of PA among resistant hypertensive patients. However, actual clinical practice in Europe does not follow these guidelines due to the lack of appropriate and cost effective screening procedures. If PA remains undiagnosed, it caused severe hypertension frequently resulting in cardiovascular complications including heart attacks and strokes.
The AA2-Ratio is a diagnostic biomarker for PA, that is superior to state-of-the-art assays and allows for a highly specific and cost effective diagnosis of PA among hypertensive patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery surgical procedures
- medical and health sciences clinical medicine cardiology cardiovascular diseases
- medical and health sciences basic medicine neurology stroke
- natural sciences chemical sciences analytical chemistry mass spectrometry
- engineering and technology medical engineering medical laboratory technology laboratory samples analysis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1030 WIEN
Austria
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.